AMRN Stock Analysis: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$14.06
-0.50 (-3.43%)
▼
5d:
-6.39%
30d:
-6.14%
90d:
-10.1%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AMRN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AMRN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.72
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$15.35
8.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $14.06, which is considered oversold relative to its 30-day fair value range of $14.21 to $14.93. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.3) compared to its historical average (18.0). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AMRN is showing sideways momentum. The price is currently testing key support at $14.01. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: AMRN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. However, the stock is trading significantly above the average Wall Street target of $12.50. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMRN is showing sideways momentum. The price is currently testing key support at $14.01. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: AMRN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. However, the stock is trading significantly above the average Wall Street target of $12.50. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.21 -
$14.93
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BEARISH: Trading 11.1% above Wall St target ($12.50)
Trading Range Analysis
30-Day Trading Range
$14.21 -
$14.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.01
Resistance Level
$15.58
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.35
Wall Street Target
$12.50
(-11.1%)
Revenue Growth (YoY)
7.4%
Earnings Growth (YoY)
-94.2%
Profit Margin
-15.5%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
14.4 vs 18.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$13.03
(-7%)
2-Year Target
$12.08
(-14%)
3-Year Target
$11.20
(-20%)
3-Yr Target (if PE normalizes)
(PE: 14→18)
$14.05
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.3 to 18.0
Stabilization Target:
$17.64
(+25.5%)
PE Expansion Potential:
+25.5%
Share & Embed Analysis
Last updated: May 18, 2026 8:04 PM ET
Data refreshes hourly during market hours. Next update: 9:04 PM
Data refreshes hourly during market hours. Next update: 9:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1210 | 65 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$253 | 65 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$218 | 62 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 57 HOLD |
